Genetic polymorphisms in estrogen metabolism and breast cancer risk in case-control studies in Japanese, Japanese Brazilians and non-Japanese Brazilians

Journal of Human Genetics

Volumn 54, Issue 4, 2009, Pages 209-215

  Shimada, Naoki ^a   Iwasaki, Motoki ^b   Kasuga, Yoshio ^c   Yokoyama, Shiro ^d   Onuma, Hiroshi ^d   Nishimura, Hideki ^e   Kusama, Ritsu ^f   Hamada, Gerson Shigeaki ^g   Nishimoto, Ines Nobuko ^h   Iyeyasu, Hirofumi ^h   Motola Jr , Juvenal ⁱ   Laginha, Fábio Martins ⁱ   Kurahashi, Norie ^b   Tsugane, Shoichiro ^b  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b NATIONAL CANCER CENTER   (Japan)

^c Nagano Matsushiro General Hospital   (Japan)

^d NAGANO RED CROSS HOSPITAL   (Japan)

^e Nagano Municipal Hospital   (Japan)

^f Nagano Hokushin General Hospital   (Japan)

^g Nikkei Disease Prevention Center   (Brazil)

^h A C CAMARGO CANCER CENTER   (Brazil)

ⁱ Hospital Perola Byington   (Brazil)

Author keywords

breast cancer; casecontrol study; cytochrome P450; immigrants; single nucleotide polymorphism

Indexed keywords

ESTROGEN;

ADULT; AGED; ARTICLE; BRAZIL; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; ESTROGEN METABOLISM; FEMALE; GENETIC ASSOCIATION; GENOTYPE; HORMONAL CARCINOGENESIS; HOSPITAL BASED CASE CONTROL STUDY; HUMAN; JAPANESE; MAJOR CLINICAL STUDY; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; AGED; AMERICAN NATIVE CONTINENTAL ANCESTRY GROUP; ASIAN CONTINENTAL ANCESTRY GROUP; BRAZIL; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CONFIDENCE INTERVALS; ESTROGENS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HUMANS; JAPAN; MIDDLE AGED; ODDS RATIO; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE;

EID: 66349091354     PISSN: 14345161     EISSN: None     Source Type: Journal    
DOI: 10.1038/jhg.2009.13     Document Type: Article

References (42)

1. Toniolo, P. G., Levitz, M., Zeleniuch Jacquotte, A., Banerjee, S., Koenig, K. L, Shore, R. E, et al. A prospective study of endogenous estrogens and breast cancer in postmeno pausal women. J. Natl Cancer Inst. 87, 190-197 (1995).
2. Mitrunen, K., Hirvonen, A. Molecular epidemiology of sporadic breast cancer. The role of polymorphic genes involved in oestrogen biosynthesis and metabolism. Mutat. Res. 544, 9-11 (2003).
3. Zhu, B. T., Conney, A. H. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 19, 1-27 (1998).
4. Kabat, G. C., Chang, C. J., Sparano, J. A., Sepkovie, D. W., Hu, X. P., Khalil, A. et al. Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epide miol. Biomarkers. Prev. 6, 505-509 (1997).
5. Fowke, J. H., Qi, D., Bradlow, H. L, Shu, X. o., Gao, Y. T, Cheng J.R. era/. Urinary estrogen metabolites and breast cancer: differential pattern of risk found with pre-versus post-treatment collection. Steroids 68, 65-72 (2003). (Pubitemid 35418304)
6. Adlercreutz, H., Gorbach, S. L, Goldin, B. R., Woods, M. N., Dwyer, J. T, Hamalainen, E. Estrogen metabolism and excretion in Oriental and Caucasian women. J. Natl Cancer Inst 86, 1076-1082 (1994).
7. Meilahn, E. N., De Stavola, B., Allen, D. S., Fentiman, I., Bradlow, H. L., Sepkovie D.W. et al. Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up. Br. J. Cancer 78, 1250-1255 (1998). (Pubitemid 28479160)
8. Eliassen, A. H., Missmer, S. A., Tworoger, S. S., Hankinson S.E. Circulating 2-hydroxy-and 16alpha-hydroxy estrone levels and risk of breast cancer among postmenopausal women. Cancer Epidemiol. Biomarkers Prev. 17, 2029-2035 (2008).
9. Huang, Z., Fasco, M. J., Figge, H. L, Keyomarsi, K., Kaminsky L.S. Expression of cytochromes P450 in human breast tissue and tumors. Drug Metab. Dispos. 24, 899-905 (1996).
10. Cribb, A. E., Knight, M. J., Dryer, D., Guernsey, J., Hender, K., Tesch, M. et al. Role of polymorphic human cytochrome P450 enzymes in estrone oxidation. Cancer Epidemiol. Biomarkers Prev. 15, 551-558 (2006).
11. Sachse, C, Brockmoller, J., Bauer, S., Roots, I. Functional significance of a C→A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br. J. Clin. Pharmacol. 47, 445-449 (1999). (Pubitemid 29161279)
12. Kuehl, P., Zhang, J., Lin, Y., Lamba, J., Assem, M., Schuetz, J. etal. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27, 383-391 (2001). (Pubitemid 32268418)
13. Miyoshi, Y, Noguchi, S. Polymorphisms of estrogen synthesizing and metabolizing genes and breast cancer risk in Japanese women. Biomed. Pharmacother. 57, 471-481 (2003).
14. Le Marchand, L., Donlon, T., Kolonel, L. N., Henderson, B. E., Wilkens L.R. Estrogen metabolism-related genes and breast cancer risk: the multiethnic cohort study. Cancer Epidemiol. Biomarkers Prev. 14, 1998-2003 ( 2005).
15. Chen, C, Huang, Y, Li, Y., Mao, Y., Xie, Y. Cytochrome P450 1A1 (CYP1A1) T3801C and A2455G polymorphisms in breast cancer risk: a meta-analysis. J. Hum. Genet. 52, 423-435 (2007).
16. Paracchini, V., Pedotti, P., Raimondi, S., Garte, S., Bradlow, H. L., Sepkovie D.W. et al. A common CYP1B1 polymorphism is associated with 2-OHE1/16-OHE1 urinary estrone ratio. Clin. Chem. Lab. Med. 43, 702-706 (2005).
17. Lurie, G., Maskarinec, G., Kaaks, R., Stanczyk, F. Z., Le Marchand, L. Association of genetic polymorphisms with serum estrogens measured multiple times during a 2-year period in premenopausal women. Cancer Epidemiol. Biomarkers Prev. 14, 1521-1527 (2005). (Pubitemid 40807356)
18. Yoshimura, K., Hanaoka, T., Ohnami, S., Ohnami, S., Kohno, T., Liu, Y. et al. Allele frequencies of single nucleotide polymorphisms (SNPs! in 40 candidate genes for gene-environment studies on cancer: data from population-based Japanese random samples. J. Hum. Gene. 48, 654-658 (2003).
19. Dunning, A. M., Dowsett, M., Healey, C. S., Tee, L, Luben, R. N., Folkerd, E. et al. Polymorphisms associated with circulating sex hormone levels in postmenopausal women. J. Natl Cancer Inst. 96, 936-945 (2004).
20. Fukuen, S., Fukuda, T, Maune, H., Ikenaga, Y., Yamamoto, I., Inaba, T. etal. Novel detection assay by PCR-RFLP and frequency of the CYP3A5 SNPs, CYP3A5*3 and*6, in a Japanese population. Pharmacogenetics 12, 331-334 (2002). (Pubitemid 34620661)
21. Hiratsuka, M., Takekuma, Y, Endo, N., Narahara, K., Hamdy, S. I., Kishikawa, Y. etal. Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population. Eur. J. Clin. Pharmacol. 58, 417-421 (2002).
22. Saeki, M., Saito, Y, Nakamura, T., Murayama, N., Kim, S. R., Ozawa, S. etal. Single nucleotide polymorphisms and haplotype frequencies of CYP3A5 in a Japanese population. Hum. Mutat. 21, 653 (2003).
23. Plummer, S. J., Conti, D. V., Paris, P. L, Curran, A. P., Casey, G., Witte J.S. CYP3A4 and CYP3A5 genotypes, haplotypes, and risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 12s, 928-932 (2003).
24. Paracchini, V., Raimondi, S., Gram, I. T, Kang, D., Kocabas, N. A., Kristensen V.H. et al. Meta- and pooled analyses of the cytochrome P-450 1B1 Val432Leu polymorphism and breast cancer: a HuGE-GSEC review. Am. J. Epidemiol. 165, 115-125 (2007).
25. Miyoshi, Y., Takahashi, Y, Egawa, C, Noguchi, S. Breast cancer risk associated with CYP1A1 genetic polymorphisms in Japanese women. Breast J. 8, 209-215 (2002).
26. Iwasaki, M., Hamada, G. S., Nishimoto, I. N., Netto, M. M., Motola, J. Jr, Laginha F.M. et al. Dietary isoflavone intake and breast cancer risk in case-control studies in Japanese, Japanese Brazilians, and non-Japanese Brazilians. Breast Cancer Res. Treat. 2008. Sep., 6 ( 2008).
27. Shen, Y, Li, D. K., Wu, J., Zhang, Z., Gao, E. Joint effects of the CYP1A1 Mspl, ERalpha Pvull, and ERalpha Xbal polymorphisms on the risk of breast cancer: results from a population-based case-control study in Shanghai, China. Cancer Epidemiol. Biomarkers Prev. 15, 342-347 (2006).
28. Han, W., Kang, D., Park, I. A., Kim, S. W., Bae, J. Y., Chung K.W. et al. Associations between breast cancer susceptibility gene polymorphisms and clinicopathological features. Clin. Cancer Res. 10, 124-130 (2004).
29. Modugno, F, Zmuda, J. M., Potter, D., Cai, C, Ziv, E., Cummings S.R. etal. Estrogen metabolizing polymorphisms and breast cancer risk among older white women. Breast Cancer Res. Treat. 93, 261-270 (2005).
30. Long, J. R., Egan, K. M., Dunning, L, Shu, X. 0., Cai, Q., Cai, H. et al. Population-based case-control study of AhR (aryl hydrocarbon receptor) and CYP1A2 polymorphisms and breast cancer risk. Pharmacogenet. Genomics 16, 237-243 (2006).
31. Rebbeck, T. R., Troxel, A. B., Walker, A. H., Panossian, S., Gallagher, S., Shatalova E.G. et al. Pairwise combinations of estrogen metabolism genotypes in postmenopausal breast cancer etiology. Cancer Epidemiol. Biomarkers Prev. 16, 444-450 (2007).
32. Kotsopoulos, J., Ghadirian, P., El Sohemy, A., Lynch, H. T, Snyder, C, Daly, M. et al. The CYP1A2 genotype modifies the association between coffee consumption and breast cancer risk among BRCA1 mutation carriers. Cancer Epidemiol. Biomarkers Prev. 16, 912-916 (2007).
33. Gulyaeva, L. R, Mikhailova, O. N., Pustylnyak, V. O.,Kim I.V.IV, Gerasimov, A. V,Krasilnikov S.E.etal. Comparative analysis of SNP in estrogen-metabolizing enzymes for ovarian, endometrial, and breast cancers in Novosibirsk, Russia. Adv. Exp. Med. Biol. 617, 359-366 (2008).
34. Shimada, T., Watanabe, J., Kawajiri, K., Sutter, T. R., Guengerich, F. P., Gillam E.M. et al. Catalytic properties of polymorphic human cytochrome P450 1B1 variants. Carcinogenesis 20, 1607-1613 (1999).
35. Gallicchio, L, Berndt, S. I., McSorley, M. A., Newschaffer, C J., Thuita, L. W., Argani, P. etal. Polymorphisms in estrogen-metabolizing and estrogen receptor genes and the risk of developing breast cancer among a cohort of women with benign breast disease. BMC Cancer 6, 173 (2006).
36. Gaudet, M. M., Chanock, S., Lissowska, J., Berndt, S. I., Yang, X. R., Peplonska, B. et al. Genetic variation of Cytochrome P450 1B1 (CYP1B1) and risk of breast cancer among Polish women. Pharrnacogenet. Genomics 16, 547-553 (2006).
37. Shou, M., Korzekwa, K. R., Brooks, E. N., Krausz, K. W., Gonzalez, F. J., Gelboin H.V. Role of human hepatic cytochrome P450 1A2 and 3A4 in the metabolic activation of estrone. Carcinogenesis 18, 207-214 (1997).
38. Huang, Z., Guengerich, F. P.,Kaminsky L.S.16Alpha-hydroxylation of estrone by human cytochrome P450 3A4/5. Carcinogenesis 19, 867-872 (1998).
39. Lee, A. J., Conney, A. H., Zhu B.T. Human cytochrome P450 3A7 has a distinct high catalytic activity for the 16alpha-hydroxylation of estrone but not 17beta-estradiol. Cancer Res. 63, 6532-6536 (2003). (Pubitemid 37255207)
40. Shen, D. D., Kunze, K. L,Thummel K.E. Enzyme-catalyzed processes of first-pass hepatic and intestinal drug extraction. Adv. Drug. Deliv. Rev. 27, 99-127 (1997).
41. Lamba, J. K., Lin, Y. S., Schuetz, E. G., Thummel K.E. Genetic contribution to variable human CYP3A-mediated metabolism. Adv. Drug. Deliv. Rev. 54, 1271-1294 (2002).
42. Vaarala, M. H., Mattila, H., Ohtonen, P., Tammela, T. L., Paavonen, T. K., Schleutker, J. The interaction of CYP3A5 polymorphisms along the androgen metabolism pathway in prostate cancer. Int. J. Cancer 122, 2511-2516 (2008).